The serologic markers of the therapeutic response of chronic necrotizing pulmonary aspergillosis (CNPA) are rarely reported. Here, we describe the changes in galactomannan (GM) antigenemia in a patient receiving oral voriconazole for CNPA, in whom a resolution of GM antigenemia to a normal level was associated with clinical improvements. The serum GM index can be an adjunctive tool for the diagnosis and monitoring of the therapeutic response of CNPA.
Date:
2011-08
Relation:
Diagnostic Microbiology and Infectious Disease. 2011 Aug;70(4):528-530.
